102 related articles for article (PubMed ID: 10050725)
1. Platelet-bound immunogloblins before and after platelet transfusion: measurement of in vivo binding.
Levin MD; de Vries W; de Veld J; Doekharan D; van der Holt B; van 't Veer MB
Br J Haematol; 1999 Feb; 104(2):397-402. PubMed ID: 10050725
[TBL] [Abstract][Full Text] [Related]
2. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients.
Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB
Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026
[TBL] [Abstract][Full Text] [Related]
3. Visual scoring versus histogram subtraction of in vivo binding of immunoglobulins against platelets after transfusion.
Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB
Cytometry B Clin Cytom; 2004 Jan; 57(1):40-6. PubMed ID: 14696062
[TBL] [Abstract][Full Text] [Related]
4. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
Sintnicolaas K; Löwenberg B
Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
[TBL] [Abstract][Full Text] [Related]
5. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
[TBL] [Abstract][Full Text] [Related]
6. A flow cytometric technique using thiazole orange to detect platelet engraftment following pediatric stem-cell transplants.
Figuerres E; Olszewski M; Kletzel M
Cytotherapy; 2001; 3(4):277-83. PubMed ID: 12171716
[TBL] [Abstract][Full Text] [Related]
7. Tracking and characterisation of transfused platelets by two colour, whole blood flow cytometry.
Hughes DL; Evans G; Metcalfe P; Goodall AH; Williamson LM
Br J Haematol; 2005 Sep; 130(5):791-4. PubMed ID: 16115139
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric platelet cross-matching to predict platelet transfusion in acute leukemia.
Sayed D; Bakry R; El-Sharkawy N; Zahran A; Khalaf MR
J Clin Apher; 2011; 26(1):23-8. PubMed ID: 21312256
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
Sandler SG
Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
[TBL] [Abstract][Full Text] [Related]
11. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
12. The value of alloantibody detection in predicting response to HLA-matched platelet transfusions.
Levin MD; Kappers-Klunne M; Sintnicolaas K; van der Holt B; van Vliet HH; Löwenberg B; van't Veer MB
Br J Haematol; 2004 Jan; 124(2):244-50. PubMed ID: 14687037
[TBL] [Abstract][Full Text] [Related]
13. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders.
Kurz M; Greinix H; Höcker P; Kalhs P; Knöbl P; Mayr WR; Pober M; Panzer S
Br J Haematol; 1996 Dec; 95(3):564-9. PubMed ID: 8943903
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of antibody response to human platelet transfusion.
Wu KK; Thompson JS; Koepke JA; Hoak JC; Flink R
J Clin Invest; 1976 Aug; 58(2):432-8. PubMed ID: 956376
[TBL] [Abstract][Full Text] [Related]
15. Antibody-mediated inhibition of the human alloimmune response to platelet transfusion in Hu-PBL-SCID mice.
Crow AR; Freedman J; Hannach B; Blanchette V; Lazarus AH
Br J Haematol; 1999 Mar; 104(4):919-24. PubMed ID: 10192460
[TBL] [Abstract][Full Text] [Related]
16. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
17. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
[TBL] [Abstract][Full Text] [Related]
18. [HLA and transfusion: new approaches with Luminex™ technology].
Giannoli C; Nguyen TK; Dubois V
Transfus Clin Biol; 2011 Apr; 18(2):218-23. PubMed ID: 21397543
[TBL] [Abstract][Full Text] [Related]
19. Serological screening, using three different test systems of platelet-transfused patients with hematologic-oncologic disorders.
Wernet D; Schnaidt M; Mayer G; Northoff H
Vox Sang; 1993; 65(2):108-13. PubMed ID: 8212664
[TBL] [Abstract][Full Text] [Related]
20. High-dose intravenous gamma globulin to suppress alloimmune destruction of donor platelets.
Junghans RP; Ahn YS
Am J Med; 1984 Mar; 76(3A):204-8. PubMed ID: 6424453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
